Drug Development Pharma - November 23, 2017
Beactica awarded 2 MSEK funding
Beactica has been awarded 2 MSEK by the Swedish Governmental Agency for Innovation Systems (Vinnova) to advance its LSD1 programme. The LSD1 programme aims to develop a novel class of compounds with the potential to radically improve the current treatment of glioblastoma, an aggressive brain tumour with 40 000 annual cases in the EU and the […]
Financing - November 23, 2017
Symcel secures 3.6 MEUR grant
Symcel has secured €3.572 million Horizon 2020 funding to support the company’s evaluation of improved combination testing of antibiotics against extensively drug-resistant bacteria in sepsis patients. The project runs over 28 months with a consortium of academic and clinical opinion leaders from Karolinska Institutet, Hospital Universitario Ramón y Cajal, Careggi University Hospital, Rigshospitalet, IHE and […]
Financing - November 8, 2017
Pelago Bioscience awarded a 3.6 MSEK grant
Pelago Bioscience has been awarded a 3.6M SEK Swelife grant to use its patented CETSAâ technique to identify new oncology biomarkers to aid the treatment of childhood leukaemia. Pelago’s CETSA MS format can be used to profile the effect of a drug on up to 6000 proteins. This will be applied to patient blood samples […]
Financing - November 7, 2017
NeuroVive conducts a directed new share issue of SEK 5.3 million
The company is conducting a directed new issue of shares, which is expected to add close to SEK 5.3 million to NeuroVive. Proceeds from the new share issue will be used primarily for continued clinical development of KL1333 and NeuroSTAT. NeuroVive’s Board of Directors has decided to conduct a private placement of approximately SEK 5.3 million to Floyd Associates […]
Financing - October 26, 2017
Nexstim raises EUR 1.75 million
Nexstim announces that it is raising new equity financing of the gross amount EUR 1.75 million via a directed issue of new shares to a London-based fund managed by City Financial Investment Company Limited. The Company’s Board of Directors resolved to issue up to 7,000,000 new shares at a subscription price of EUR 0.25 per […]
Biotech Business - August 29, 2017
Athera completes a 57 million SEK financing
Athera Biotechnologies has completed a 57 million SEK financing from current major owners, The Foundation for Baltic and East European Studies (Östersjöstiftelsen), Industrifonden and Linc AB, together with new investor Ribbskottet AB, an investment company lead by Anders Bladh. Mr Bladh has a long background from international asset management, finance and banking as well as […]
